Latest filing published 06 Jul 2022 for Innate Pharma, €24k. Read the official filing
Herve Brailly (chief executive) discloses dealings in Innate Pharma to AMF. In total, 25 filings cover trades dated from 5 February 2021 to 30 June 2022.
No open-market purchase appears, only 21 sales worth €451k. Besides market trades, the filings include 2 option exercises. Since January 2022: no purchases and 8 sales on the market.
The newest entry dates from 6 July 2022: an open-market sale of €24k, in Innate Pharma. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from AMF. Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
24 of 24 declarations